Characterization of renal angiotensin - converting enzyme 2 in diabetic nephropathy

Tikellis, Christos, Johnston, Colin I., Forbes, Josephine M., Burns, Wendy C., Burrell, Louise M., Risvanis, John and Cooper, Mark E. (2003) Characterization of renal angiotensin - converting enzyme 2 in diabetic nephropathy. Hypertension, 41 3: 392-397. doi:10.1161/01.HYP.0000060689.38912.CB

Author Tikellis, Christos
Johnston, Colin I.
Forbes, Josephine M.
Burns, Wendy C.
Burrell, Louise M.
Risvanis, John
Cooper, Mark E.
Title Characterization of renal angiotensin - converting enzyme 2 in diabetic nephropathy
Journal name Hypertension   Check publisher's open access policy
ISSN 0194-911X
Publication date 2003-03-01
Sub-type Article (original research)
DOI 10.1161/01.HYP.0000060689.38912.CB
Open Access Status Not yet assessed
Volume 41
Issue 3
Start page 392
End page 397
Total pages 6
Place of publication Philadelphia, PA, United States
Publisher Lippincott Williams & Wilkins
Language eng
Abstract ACE2, initially cloned from a human heart, is a recently described homologue of angiotensin-converting enzyme (ACE) but contains only a single enzymatic site that catalyzes the cleavage of angiotensin I to angiotensin 1-9 [Ang(1-9)] and is not inhibited by classic ACE inhibitors. It also converts angiotensin II to Ang(1-7). Although the role of ACE2 in the regulation of the renin-angiotensin system is not known, the renin-angiotensin system has been implicated in the pathogenesis of diabetic complications and in particular in diabetic nephropathy. Therefore, the aim of this study was to assess the possible involvement of this new enzyme in the kidney from diabetic Sprague-Dawley rats to compare and contrast it to ACE. ACE2 and ACE gene and protein expression were measured in the kidney after 24 weeks of streptozocin diabetes. ACE2 and ACE mRNA levels were decreased in diabetic renal tubules by ≈50% and were not influenced by ACE inhibitor treatment with ramipril. By immunostaining, both ACE2 and ACE protein were localized predominantly to renal tubules. In the diabetic kidney, there was reduced ACE2 protein expression that was prevented by ACE inhibitor therapy. The identification of ACE2 in the kidney, its modulation in diabetes, and the recent description that this enzyme plays a biological role in the generation and degradation of various angiotensin peptides provides a rationale to further explore the role of this enzyme in various pathophysiological states including diabetic complications.
Keyword Angiotensin
Angiotensin-converting enzyme
Diabetes mellitus
Diabetic nephropathy
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: Mater Research Institute-UQ (MRI-UQ)
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 205 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 236 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 15 Dec 2014, 11:01:52 EST by System User on behalf of Learning and Research Services (UQ Library)